[go: up one dir, main page]

PL392566A1 - Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego, sposób ich otrzymywania, kompozycja je zawierająca oraz zastosowanie - Google Patents

Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego, sposób ich otrzymywania, kompozycja je zawierająca oraz zastosowanie

Info

Publication number
PL392566A1
PL392566A1 PL392566A PL39256603A PL392566A1 PL 392566 A1 PL392566 A1 PL 392566A1 PL 392566 A PL392566 A PL 392566A PL 39256603 A PL39256603 A PL 39256603A PL 392566 A1 PL392566 A1 PL 392566A1
Authority
PL
Poland
Prior art keywords
hyaluronic acid
derivatives
hialuronic acid
obtaining
application
Prior art date
Application number
PL392566A
Other languages
English (en)
Other versions
PL216861B1 (pl
Inventor
Luca Gilda De
Bettolo Ronaldo Marini
Luisa Maria Migneco
Original Assignee
Fidia Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici S.P.A. filed Critical Fidia Farmaceutici S.P.A.
Publication of PL392566A1 publication Critical patent/PL392566A1/pl
Publication of PL216861B1 publication Critical patent/PL216861B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Epoxy Compounds (AREA)
PL392566A 2002-10-18 2003-10-10 Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego, sposób ich otrzymywania, kompozycja je zawierająca oraz zastosowanie PL216861B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000271A ITPD20020271A1 (it) 2002-10-18 2002-10-18 Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Publications (2)

Publication Number Publication Date
PL392566A1 true PL392566A1 (pl) 2010-11-22
PL216861B1 PL216861B1 (pl) 2014-05-30

Family

ID=32104794

Family Applications (2)

Application Number Title Priority Date Filing Date
PL392566A PL216861B1 (pl) 2002-10-18 2003-10-10 Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego, sposób ich otrzymywania, kompozycja je zawierająca oraz zastosowanie
PL03376349A PL376349A1 (pl) 2002-10-18 2003-10-10 Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL03376349A PL376349A1 (pl) 2002-10-18 2003-10-10 Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego

Country Status (22)

Country Link
US (2) US7897584B2 (pl)
EP (2) EP1560854B1 (pl)
JP (1) JP4704753B2 (pl)
KR (1) KR101076414B1 (pl)
CN (1) CN1705683B (pl)
AT (1) ATE420117T1 (pl)
AU (1) AU2003267441B2 (pl)
BR (1) BR0315431A (pl)
CA (2) CA2502531C (pl)
DE (1) DE60325760D1 (pl)
DK (1) DK1560854T3 (pl)
ES (2) ES2544481T3 (pl)
HR (1) HRP20050416B1 (pl)
IL (1) IL168086A (pl)
IT (1) ITPD20020271A1 (pl)
NO (1) NO333042B1 (pl)
NZ (2) NZ540034A (pl)
PL (2) PL216861B1 (pl)
PT (1) PT1560854E (pl)
RU (1) RU2384593C2 (pl)
SI (1) SI1560854T1 (pl)
WO (1) WO2004035629A2 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
CA2491216C (en) 2002-06-26 2012-01-03 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
US8021684B2 (en) 2004-07-09 2011-09-20 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
CA2614312C (en) * 2005-07-06 2014-02-18 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
WO2007083984A1 (en) * 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
AU2007280846B2 (en) 2006-08-04 2012-06-14 Novozymes Biopharma Dk A/S Branched hyaluronic acid and method of manufacture
WO2008089257A2 (en) * 2007-01-16 2008-07-24 Cappella, Inc. Drug eluting medical device using polymeric therapeutics with transglutaminase substrates
ITMI20071267A1 (it) * 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
ITMI20071341A1 (it) * 2007-07-05 2009-01-06 Fidia Farmaceutici Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
EP2242514B1 (en) * 2008-01-30 2015-09-30 University Of Kansas Intralymphatic chemotherapy drug carriers
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
IT1391006B1 (it) * 2008-10-08 2011-10-27 Fidia Farmaceutici Uso terapeutico di nuove preparazioni farmaceutiche contenenti farmaci antitumorali legati all'acido ialuronico nel trattamento delle neoplasie
ES2525066T3 (es) 2008-04-22 2014-12-17 Fidia Farmaceutici S.P.A. Uso terapéutico de preparaciones farmacéuticas que contienen fármacos antitumorales unidos a ácido hialurónico en el tratamiento de neoplasias
WO2010030342A2 (en) * 2008-09-09 2010-03-18 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
EP2360188B1 (en) 2008-11-05 2014-09-17 National University Corporation Tokyo Medical and Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
IT1399351B1 (it) * 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR20110032561A (ko) * 2009-09-23 2011-03-30 포항공과대학교 산학협력단 약물 전달체의 표적 특이성 조절 방법, 표적 특이적 약물 전달체, 및 표적-비특이적 약효 장기 지속성 약물 전달체
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
WO2012086857A1 (ko) * 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
WO2013131520A2 (en) 2012-03-06 2013-09-12 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
EP2801379B1 (en) * 2012-03-27 2017-03-08 Terumo Kabushiki Kaisha Coating composition and medical device
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
KR102130864B1 (ko) 2012-09-05 2020-07-08 추가이 세이야쿠 가부시키가이샤 아미노산 및 스테릴기가 도입된 히알루론산 유도체
US9635795B2 (en) 2012-10-23 2017-04-25 International Business Machines Corporation Multiple expansion card insertion and extraction tool
CN103641925B (zh) * 2012-11-27 2016-08-17 王晖 水溶性多聚糖与紫杉烷类化合物的共价聚化合物，其制备方法及医药用途
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10675354B2 (en) 2013-07-10 2020-06-09 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
JP6453214B2 (ja) * 2013-07-10 2019-01-16 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
CN103861116A (zh) * 2014-03-06 2014-06-18 沈阳药大制剂新技术有限公司 一种抗肿瘤药物的前体药物及其制备和应用
CN106573957B (zh) * 2014-07-31 2021-10-26 塞巴斯蒂安诺·舒托 由透明质酸和肌肽得到的衍生物
CN104198707B (zh) * 2014-09-12 2016-09-14 范飞舟 N-乙酰氨基葡萄糖在制备检测肿瘤的试剂盒中的应用
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
WO2016102446A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CN107108761B (zh) * 2015-01-09 2020-06-30 生化学工业株式会社 硫酸软骨素衍生物和膀胱疾病处置剂
JP2018516277A (ja) * 2015-05-29 2018-06-21 アルバトロス テクノロジーズ リミテッドＡｌｂａｔｒｏｓｓ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 薬物送達用架橋ヒアルロン酸及びそれを用いた医薬製剤
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN108178803B (zh) * 2017-09-25 2020-03-10 温州医科大学 一种载药的肉桂醛-葡聚糖聚合物自组装纳米粒的制备及其抗肿瘤应用
JP7221211B2 (ja) 2017-11-15 2023-02-13 中外製薬株式会社 ポリエチレングリコールにより修飾されたヒアルロン酸誘導体
CN108219029A (zh) * 2018-03-22 2018-06-29 盐城师范学院 一种水溶性卡巴他赛抗癌药物的制备方法
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
WO2019242691A1 (zh) * 2018-06-20 2019-12-26 圣多利康制药责任有限公司 紫杉烷-脂类-多聚糖双型偶联体、其制备方法及用途
IT201800009731A1 (it) * 2018-10-25 2020-04-25 Fidia Farm Spa Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
CN111588914A (zh) * 2019-12-31 2020-08-28 辽宁垠艺生物科技股份有限公司 介入或植入医疗器械的药物涂层及其制备方法
IT202000007747A1 (it) * 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel
CN111892668B (zh) * 2020-07-03 2022-07-12 广东工业大学 一种化合物及其制备方法、荧光探针和抗肿瘤药物
CA3179897A1 (en) * 2020-07-15 2022-01-20 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
CN114870031B (zh) * 2022-05-20 2023-07-07 四川大学 一种cd44靶向的紫杉烷类纳米晶体及其制备方法与应用
WO2024038087A1 (en) * 2022-08-16 2024-02-22 Synartro Ab Method for preparing sterile compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
AU652784B2 (en) * 1990-10-18 1994-09-08 Shiseido Company Ltd. Combination of hyaluronic acid with medicinal ingredient and production thereof
JP2604930B2 (ja) * 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
DE69425464T2 (de) * 1993-02-26 2001-05-23 Drug Delivery System Institute, Ltd. Polysaccharidderivat und wirkstoffträger
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
SI0932399T1 (sl) * 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
CA2175282A1 (en) 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
CA2332802A1 (en) * 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Conjugate of therapeutic agent for joint disease and hyaluronic acid
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
JP2002523407A (ja) 1998-08-21 2002-07-30 ファルマヘミー ベー．フェー． パクリタキセルの水溶性類似体およびプロドラッグ
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
JP4215429B2 (ja) 1999-12-28 2009-01-28 バイオニケ ライフ サイエンシーズ インコーポレイテッド 癌治療におけるヒアルロン酸
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e

Also Published As

Publication number Publication date
CN1705683B (zh) 2010-04-28
IL168086A (en) 2010-11-30
HRP20050416B1 (hr) 2013-09-30
NO20052399L (no) 2005-05-18
US20060116346A1 (en) 2006-06-01
RU2005115116A (ru) 2006-01-20
AU2003267441A1 (en) 2004-05-04
NO333042B1 (no) 2013-02-18
KR20050065595A (ko) 2005-06-29
PT1560854E (pt) 2009-04-15
ES2320439T3 (es) 2009-05-22
CA2502531C (en) 2012-10-02
CA2502531A1 (en) 2004-04-29
BR0315431A (pt) 2005-08-16
CA2783175A1 (en) 2004-04-29
WO2004035629A3 (en) 2004-06-24
US7897584B2 (en) 2011-03-01
EP2045270A2 (en) 2009-04-08
RU2384593C2 (ru) 2010-03-20
KR101076414B1 (ko) 2011-10-25
NO20052399D0 (no) 2005-05-18
WO2004035629A9 (en) 2005-07-07
SI1560854T1 (sl) 2009-06-30
JP2006504747A (ja) 2006-02-09
HK1082753A1 (en) 2006-06-16
WO2004035629A2 (en) 2004-04-29
CN1705683A (zh) 2005-12-07
DK1560854T3 (da) 2009-04-20
HRP20050416A2 (en) 2006-02-28
PL216861B1 (pl) 2014-05-30
EP2045270A3 (en) 2009-06-03
ES2544481T3 (es) 2015-08-31
EP1560854A2 (en) 2005-08-10
NZ547668A (en) 2008-04-30
EP1560854B1 (en) 2009-01-07
ATE420117T1 (de) 2009-01-15
US20110159052A1 (en) 2011-06-30
EP2045270B1 (en) 2015-05-06
CA2783175C (en) 2013-12-24
ITPD20020271A1 (it) 2004-04-19
NZ540034A (en) 2007-11-30
AU2003267441B2 (en) 2010-01-14
JP4704753B2 (ja) 2011-06-22
US8034795B2 (en) 2011-10-11
DE60325760D1 (de) 2009-02-26
PL376349A1 (pl) 2005-12-27
WO2004035629A8 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
PL392566A1 (pl) Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego, sposób ich otrzymywania, kompozycja je zawierająca oraz zastosowanie
DE60031268D1 (de) Verfahren und zusammansetzung zur behandlung von krebs
PT1928882E (pt) (s)-n-metilnaltrexona, processo para a sua síntese e sua utilização farmacêutica
TW200519106A (en) Organic compounds
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
WO2007069272A3 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
GB0313612D0 (en) Organic compounds
PL1797088T3 (pl) Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
GB0317491D0 (en) Organic compounds
EA200701688A1 (ru) Замещённые пирролы, содержащие их композиции, способ получения и применение
LV15575A (lv) Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
GB2430365B (en) High-purity texaphyrin metal complexes
BRPI0207141B8 (pt) processo para preparar compostos, uso de compostos, composição farmacêutica e método para tratamento de câncer
ATE440826T1 (de) Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
EP1931735A4 (en) HIGH-purity TEXAPHYRINMETAL COMPLEXES
ATE537162T1 (de) Vitamin-d-derivate, die auf den nuklearen vitamin-d-rezeptor wirken, deren herstellung und deren anwendungen
GEP20115229B (en) Novel camptothecin analogues compounds, a method for preparation thereof and pharmaceutical compositions containing them
SG160346A1 (en) Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
UA93197C2 (ru) Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)